

CyGenics Ltd • Australia • Level 4 • 414 Lonsdale Street • Melbourne 3000
Phone 61 (0)3 9642 5580 • Facsimile 61 (0)3 9642 5581
Singapore • 600 North Bridge Road • #12-09/10 Parkview Square • Singapore 188778
Phone (65) 6238 0808 • Facsimile (65) 6295 1108 • www.cygenics.com



For Immediate Release

CyGenics Appoints Ex-Baxter International Senior Executive As New Board Member

15th February 2006 – Leading cell therapy services company CyGenics Ltd. (ASX: CYN) today announced the appointment of Mr Alberto J. Bautista to its Board of Directors, as a non-executive director.

Mr Bautista is an industry veteran of many years' standing, and was appointed Senior Consultant, Global Alliances & Corporate Development for CyGenics, in January 2005. Utilising his industry background, extensive contacts and expertise, he provided strategic advice and support to CyGenics for its global expansion. He also facilitated high level discussions on potential mergers and acquisitions, and provided guidance in the organisational structure and staffing of the group.

Prior to this appointment, Mr Bautista was with Baxter International for nearly 30 years. Baxter assists healthcare professionals and their patients with the treatment of complex medical conditions, including cancer, haemophilia, immune disorders, kidney disease, and trauma worldwide. The NYSE-listed company had sales in 2005 of US\$9.8 billion. Mr Bautista has worked for Baxter in several countries on four continents, most recently as a Vice President with its Japan office, where he was responsible for US\$300 million in sales. From 1997 to 2001, he was President of Baxter Healthcare Asia. From 1992 to 1997, he was responsible for four Baxter businesses in this region, tripling the company's sales in those five years.

Mr Bautista graduated with a Bachelors in Industrial Engineering from the University of the Philippines, and holds a Masters in Management from the Sloan School of the Massachusetts Institute of Technology.

"Al has made a valuable contribution over the past year," said Chris Fullerton, Chairman, CyGenics. "I heartily welcome him to the board, where his expertise, experience and broad industry contacts will enhance the level of support and guidance which directors can offer our management team, and will add depth to the board's corporate governance role."



About CyGenics

CyGenics is a cell therapy company focused on the development and commercialisation of adult stem cell-related products, services, applications and technologies. From its headquarters in Australia, CyGenics operates four subsidiaries: Singapore-based CordLife (tissue banking services, in particular, cord blood banking) and Cell Sciences (consumable cell culture products), and Cytomatrix (cell therapeutics and technology development) based in Boston, USA, and CytoVations (new product development) based in New Jersey, USA. CyGenics is listed on the Australian Stock Exchange, under the symbol CYN. For more information, please visit www.cygenics.com.

For more information, please contact:

General Inquiries

Steven Fang, CEO, CyGenics Ltd Mob: +61 (0)400 933 243 Email: steven.fang@cygenics.com	Ian Brown, COO, CyGenics Ltd Mob: +61 (0)438 565 212 Email: ian.brown@cygenics.com
--	--

Media Inquiries

Rebecca Piercy, Buchan Consulting Ph: +61 (0)3 9866 4722 Mob: +61 (0)422 916 422 Email: rpiercy@bcg.com.au	Ronald Hee, CyGenics Ltd Ph: +65 6238 0808 Mob: +65 9061 9098 Email: ronald.hee@cygenics.com
---	--